China's First Class III TMS Certificate Names One Diagnosis, Not a Modality

In May 2025, China's National Medical Products Administration granted the country's first Class III registration certificate for a psychiatric transcranial magnetic stimulation (TMS) device, closing an almost decade-long gap between how these machines were classified and how they were actually being used. The certificate went to Wuhan Yiruide Medical Equipment New Technology Co., Ltd., and its approved indication is a single diagnosis: depression. A 2017 rule had already assigned psychiatric TMS to the stricter Class III category, reserved for higher-risk devices requiring a full clinical-trial dossier, but enforcement did not catch up with the classification until this filing eight years later.

Trade press covering the certificate reports that 28 of the 29 TMS devices previously cleared for the Chinese market carried Class II registration – a category with lighter evidentiary requirements – even when sold into psychiatric settings. Industry commentary describes this as use "beyond the approved scope" of the underlying certificates: devices cleared for other purposes were, in practice, marketed and used for psychiatric indications the certificates did not specify. The new Class III certificate is the first to name depression explicitly as the covered use, rather than leaving the indication implicit or generic.

The regulatory shift comes as the underlying market has grown quickly, though the two are only loosely connected. A separate market-data report (innomd.com, February 2026, citing device-market data provider 智械云) puts 2025 purchases of magnetic-stimulation devices across China – the whole category, every manufacturer and indication, not Wuhan Yiruide's device specifically – at 3,198 units, up 195.29% from the year before; procurement value reached roughly 880 million yuan, a 134.67% increase over 2024's 375 million yuan (itself up from 355 million yuan in 2023). Tertiary ("Class 3A") hospitals – the highest tier in China's hospital ranking system – accounted for 1,140 of the 2025 units, or 35.65% of purchases; non-medical institutions, which the report does not further categorize, bought 536 units, or 16.76%. That report cites the new Class III certificate as one contextual driver among several – alongside equipment-renewal policy and expansion into pain and cognitive indications – not as the cause of the surge on its own. Separately, industry commentary suggests the stricter classification could make TMS devices eligible for broader inclusion in national health insurance reimbursement, though no coverage decision has been reported.

None of the coverage locates the certificate within a specific stimulation protocol: reports describe the regulatory category and the named indication, not the frequency, session count, or target region the certificate covers. That gap matters for reading this development narrowly. The certificate answers one question – which diagnosis this device's Class III approval names – without answering a second one: which protocol, at what parameters, was the evidentiary basis for that approval. A depression-only certificate is a narrower claim than "TMS works" in general, but it is not yet a fully specified one.

The trajectory is informative on its own terms regardless of those specifics: a device category operated for years under a lower-risk classification than its actual clinical use warranted, then a first certificate arrived tying the higher classification to one diagnosis rather than to the modality as a whole. Whether the other 28 Class II devices update their registrations, whether other manufacturers pursue Class III certificates of their own, and whether reimbursement follows are all open questions the current reporting does not resolve.